Technical Analysis for CTIC - Cell Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
CTIC closed up 0.79 percent on Wednesday, January 16, 2019, on 39 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|See historical CTIC trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 16||NR7||Range Contraction||0.00%|
|Jan 16||Wide Bands||Range Expansion||0.00%|
|Jan 15||New Downtrend||Bearish||0.79%|
|Jan 15||Hammer Candlestick||Bullish||0.79%|
|Jan 15||Wide Bands||Range Expansion||0.79%|
|Jan 15||Overbought Stochastic||Strength||0.79%|
|Jan 14||New Uptrend||Bullish||-0.78%|
|Jan 14||Weak + Overbought||Other||-0.78%|
|Jan 14||Wide Bands||Range Expansion||-0.78%|
|Jan 14||Overbought Stochastic||Strength||-0.78%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Cell Therapeutics, Inc. engages in the acquisition, development, and commercialization of treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma. It is also developing Opaxio, a chemotherapeutic agent that is in Phase III clinical trials for the treatment of ovarian cancer; in Phase II clinical trials for the treatment of malignant brain cancer; and in Phase I-II clinical trials for the treatment of head and neck cancer. In addition, the company is developing Pacritinib, a Janus kinase 2 inhibitor that is in Phase III clinical trials for the treatment of myelofibrosis; Tosedostat, an aminopeptidase inhibitor that is in Phase I-II clinical trials for the treatment of acute myeloid leukemia; and Brostallicin, which is in Phase II clinical trials for the treatment of triple-negative breast cancer. It has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CTIC news...
|52 Week High||5.36|
|52 Week Low||0.6|
|200-Day Moving Average||2.7467|
|50-Day Moving Average||1.416|
|20-Day Moving Average||1.107|
|10-Day Moving Average||1.274|
|Average True Range||0.1356|
|Chandelier Exit (Long, 3 ATRs )||1.0732|
|Chandelier Exit (Short, 3 ATRs )||1.0068|
|Upper Bollinger Band||1.5396|
|Lower Bollinger Band||0.6744|
|Percent B (%b)||0.7|
|MACD Signal Line||-0.0711|
|Market Cap||40.61 Million|
|Num Shares||31.7 Million|
|Price-to-Earnings (P/E) Ratio||-0.68|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||1.40|
|Resistance 3 (R3)||1.40||1.37||1.38|
|Resistance 2 (R2)||1.37||1.34||1.37||1.37|
|Resistance 1 (R1)||1.32||1.32||1.35||1.32||1.37|
|Support 1 (S1)||1.24||1.26||1.27||1.24||1.19|
|Support 2 (S2)||1.21||1.24||1.21||1.19|
|Support 3 (S3)||1.16||1.21||1.18|
|Support 4 (S4)||1.16|